Literature DB >> 14961770

Presentation and outcome of 93 cases of craniopharyngioma.

B Larijani1, M H Bastanhagh, M Pajouhi, F Kargar Shadab, A Vasigh, S Aghakhani.   

Abstract

We studied a series of 93 patients diagnosed with craniopharyngioma during a 15-year period with respect to presenting symptom, clinical course and management. The majority (62%) of patients were men, and had presented with neurological symptoms (75%), with headaches (82%) being the most common presenting symptom. The incidence of certain endocrine and ophthalmic symptoms varied little from that in the literature, on the other hand, the incidence of certain other symptoms did differ markedly from the literature. For example, loss of libido and amenorrhoea were seen at a much lower frequency than that stated in the literature. Hypertension, sensorimotor symptoms and urinary incontinence were not seen at all in our patients. In most cases diagnosis was made by a cranial CT scan, which is more sensitive than plain radiography for detection of enlarged sella turcica (69% vs. 24%; P < 0.001). In over 90% of cases, therapy consisted of removal of a variable portion of the tumour, with or without radiotherapy. Post-operative mortality was substantially reduced in cases treated by radiotherapy (P < 0.05). The most common post-operative complications in all cases were recurrence of disease, panhypopituitarism and diabetes insipidus.

Entities:  

Mesh:

Year:  2004        PMID: 14961770     DOI: 10.1111/j.1365-2354.2003.00433.x

Source DB:  PubMed          Journal:  Eur J Cancer Care (Engl)        ISSN: 0961-5423            Impact factor:   2.520


  9 in total

1.  Comprehensive analysis of Iranian reports of pediatric central nervous system tumors.

Authors:  Narjes Mehrvar; Azim Mehrvar; Mohammad Esmaeil Akbari; Ibrahim Qaddoumi
Journal:  Childs Nerv Syst       Date:  2017-05-29       Impact factor: 1.475

Review 2.  Endocrine manifestations of craniopharyngioma.

Authors:  Isil Halac; Donald Zimmerman
Journal:  Childs Nerv Syst       Date:  2005-07-27       Impact factor: 1.475

3.  Review of management and morbidity of pediatric craniopharyngioma patients in a low-middle-income country: a 12-year experience.

Authors:  Nisreen Amayiri; Maisa Swaidan; Yocoub Yousef; Hadeel Halalsheh; Ramiz Abu-Hijlih; Sima Kalaldeh; Maha Barbar; Maher Elayyan; Nesreen Faqih; Maysa Al-Hussaini; Mustafa Mehyar; Ute Bartels; James Drake; Awni Musharbash; Eric Bouffet
Journal:  Childs Nerv Syst       Date:  2017-04-28       Impact factor: 1.475

4.  Clinical impact of craniopharyngioma classification based on location origin: a multicenter retrospective study.

Authors:  Wenfu Hu; Binghui Qiu; Fen Mei; Jian Mao; Lizhi Zhou; Fan Liu; Jun Fan; Yi Liu; Ge Wen; Songtao Qi; Yun Bao; Jun Pan
Journal:  Ann Transl Med       Date:  2021-07

5.  Acute presentation of craniopharyngioma in children and adults in a Danish national cohort.

Authors:  E H Nielsen; J O Jørgensen; P Bjerre; M Andersen; C Andersen; U Feldt-Rasmussen; L Poulsgaard; L Ø Kristensen; J Astrup; J Jørgensen; P Laurberg
Journal:  Pituitary       Date:  2013-12       Impact factor: 4.107

6.  Endocrinologic, neurologic, and visual morbidity after treatment for craniopharyngioma.

Authors:  Michael E Sughrue; Isaac Yang; Ari J Kane; Shanna Fang; Aaron J Clark; Derrick Aranda; Igor J Barani; Andrew T Parsa
Journal:  J Neurooncol       Date:  2010-06-10       Impact factor: 4.130

7.  Craniopharyngioma presenting with severe hyponatremia, hyponatremia-induced myopathy, and panhypopituitarism: a case report.

Authors:  M D S A Dilrukshi; G V N Sandakumari; P K Abeysundara; T Chang
Journal:  J Med Case Rep       Date:  2017-02-05

Review 8.  Current Diagnostic Status of Pheochromocytomaand Future Perspective: A Mini Review.

Authors:  Fatemeh Khatami; Seyed Mohammad Tavangar
Journal:  Iran J Pathol       Date:  2017-07-01

9.  Evaluation and management of amenorrhea related to congenital sex hormonal disorders.

Authors:  Ju Young Yoon; Chong Kun Cheon
Journal:  Ann Pediatr Endocrinol Metab       Date:  2019-09-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.